Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
about
Concepts and targets in triple-negative breast cancer: recent results and clinical implicationsSacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Association of tumor TROP2 expression with prognosis varies among lung cancer subtypesTrop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).Emerging therapeutic targets in metastatic progression: A focus on breast cancer.STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.Prospects and progress of antibody-drug conjugates in solid tumor therapies.Strategies and challenges for the next generation of antibody-drug conjugates.New agents for the management of resistant metastatic breast cancer.The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.
P2860
Q28078992-7031DBCC-756F-4637-AC69-0D5E4AEAB5BAQ30101057-91DE62FC-83EB-4525-86FB-D4BD97A63955Q33709864-D6A29F93-7F61-4F43-B7E9-55C42440B6F1Q36356001-1BC92EF3-EDB8-4A98-93D4-365E036D8BD4Q36854062-0692E3CA-8A14-4CC1-869C-CCB7606B864CQ37662264-6C6E13FE-4619-4508-8954-B247B29CF8ADQ37706198-D1DE73E5-D746-4649-BCFE-815F1AC7E3C2Q38375607-D7A8858C-C5DC-4BAB-A0C0-CD3FD5571910Q38798525-3763C816-DB1F-4712-9775-88D25AC2B7DBQ39182945-FC65294D-525D-46BB-ABAD-7DE8F2F0A070Q48240854-FF860523-7575-42C0-A644-5CE8CD3C3973Q55508847-A94DAA01-2D57-44DF-8CF0-1E2449BABD1A
P2860
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Enhanced Delivery of SN-38 to ...... ugate (Sacituzumab Govitecan).
@en
type
label
Enhanced Delivery of SN-38 to ...... ugate (Sacituzumab Govitecan).
@en
prefLabel
Enhanced Delivery of SN-38 to ...... ugate (Sacituzumab Govitecan).
@en
P2093
P1476
Enhanced Delivery of SN-38 to ...... ugate (Sacituzumab Govitecan).
@en
P2093
Chien-Hsing Chang
David M Goldenberg
Edmund A Rossi
Robert M Sharkey
Serengulam V Govindan
Thomas M Cardillo
William J McBride
P304
P356
10.1158/1078-0432.CCR-15-0670
P407
P577
2015-06-23T00:00:00Z